Strong Growth Ahead: Giant-Cell Arteritis Market Size To Grow At Arecord 5% Cagr By 2029

The Giant-Cell Arteritis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Giant-Cell Arteritis Market Size Expected to Be by 2034?
The giant-cell arteritis market has experienced strong growth in recent years. It will increase from $1.07 billion in 2024 to $1.12 billion in 2025, at a compound annual growth rate (CAGR) of 5.3%. The growth in the past period can be attributed to epidemiological studies, genetic insights, greater adoption of biologics, improvements in diagnostic techniques, and the development of targeted therapies and biologics.

The giant-cell arteritis market is set to grow steadily, reaching $1.36 billion by 2029 at a CAGR of 5.0%. This growth is driven by increasing diagnosis rates, an aging population, rising healthcare spending, growing patient advocacy, and the expansion of treatments into new geographic regions. Major trends include advancements in the identification and validation of biomarkers, development of therapies targeting specific molecular pathways, the use of advanced imaging techniques, innovations in drug delivery systems, and the use of AI algorithms for predictive analytics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17162

What Are the Emerging Segments Within the Giant-Cell Arteritis Market?
The giant-cell arteritis market covered in this report is segmented -

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin
2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action
3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:
1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

What Long-Term Drivers Are Shaping Giant-Cell Arteritis Market Trends?
The emphasis on personalized treatment is projected to drive the giant-cell arteritis market. Personalized medicine allows treatments to be tailored to individual genetic and immunological profiles, improving outcomes in diseases like giant-cell arteritis (GCA). The Personalized Medicine Coalition reported in February 2024 that personalized drugs made up over one-third of FDA approvals for the fourth consecutive year, including 16 new therapies in 2023-seven for cancer and three for other conditions. Thus, personalized care approaches are supporting growth in the giant-cell arteritis market.

Who Are the Top Competitors in Key Giant-Cell Arteritis Market Segments?
Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

What Trends Are Expected to Dominate the Giant-Cell Arteritis Market in the Next 5 Years?
Principal businesses in the giant-cell arteritis market are focusing on creating novel products like biosimilars to broaden the range of treatment alternatives and answer the unserved health needs of patients. Biosimilars, which are biological drugs that exhibit a high level of similarity to already authorized biological products, exhibit no significant clinical variations concerning safety, efficacy, and potency. For example, in April 2024, the German healthcare firm Fresenius SE & Co. KGaA rolled out Tocilizumab-aazg in the US to treat chronic autoimmune diseases. Approved for medical conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis, the biosimilar product's authorization was based on information from a randomized, single-dose, double-blind, parallel phase 1 trial contrasting its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient demographics.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Which Regions Are Becoming Hubs for Giant-Cell Arteritis Market Innovation?
North America was the largest region in the giant-cell arteritis market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Giant-Cell Arteritis Market?
2. What is the CAGR expected in the Giant-Cell Arteritis Market?
3. What Are the Key Innovations Transforming the Giant-Cell Arteritis Industry?
4. Which Region Is Leading the Giant-Cell Arteritis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.